维普期刊资源整合服务平台（V6.5）

56篇 您的检索式：作者名="Witzig E"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘	Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari	2013	Gut2013，，11：	2
2	Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘	Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari	2013	Gut2013，，11：	2
3	Review of 1027 patients with newly diagnosed multiple myeloma显示文摘	KYLE R A GERTZ M A WITZIG T E	2003	Mayo Clin Proc2003，78，1：	1
4	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma显示文摘	Kumar S Witzig T E Dispenzieri A		0，，：	1
5	Introduction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents显示文摘	Witzig T E Timm M Stenson Mary	2000	Clinical Cancer Research2000，6，2：	1
6	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity显示文摘	Mathew P Ahmann G J Witzig T E	1995	Br J Haematol1995，90，：	1
7	Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents显示文摘	THOMAS E WITZIG MICHAEL TIMM	2000	Clinical Cancer Res2000，6，：	1
8	The role of adhesion receptors in the pathogenesis of multiple myeloma显示文摘	WITZIG T E	1999	Hematol Oncol Clin North Am1999，13，：	1
9	Inhibition of the phosphatidylinositol 3-kinase/mamm-alian target of rapamycin pathway in hematologic malignancies显示文摘	Witzig T E Kaufmann S H	2006	Curr Treat Options Oncol2006，7，：	1
10	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma 显示文摘	Thompson M A Witzig T E Kumar S	2003	Br J Haematol2003，123，2：	1
11	Radioimmunotherapy for B-cell non-Hodgkin lymphoma显示文摘	Thomas E Witzig	2006	Best Practice & Research Clinical Haematology2006，19，4：	1
12	Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy 显示文摘	Witzig T E Bossy B Kimlinger T	2002	Clin Cancer Res2002，8，：	1
13	Targeting apoptosis pathways in cancer therapy显示文摘	Ghobrial I M Witzig T E Adjei A A	2005	CA Cancer J Clin2005，55，3：	1
14	Targeting apoptosis pathways in cancer therapy 显示文摘	GHOBRIAL I M WITZIG T E ADJEI A A	2005	CA Cancer J Clin2005，55，3：	1
15	Epidermoid cysts,sulci,and mucosal bridges of the true vocal cord:A report of 157 cases显示文摘	Cornut G Bouchayer M Witzig E Roch JB Loire R	1985	The Laryngoscope1985，95，9：	1
16	Randomized controlled trial of yttrium-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma显示文摘	WITZIG T E GORDON L I CABANILLAS F	2002	J Clin Oncol2002，20，：	1
17	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma 显示文摘	EMMANOUILIDES C WITZIG T E GORDON L I	2006	Leuk Lymphoma2006，47，：	1
18	Targeting Apoptosis Pathways in Cancer Therapy 显示文摘	GHOBRIAL I M WITZIG T E ADJEI A A	2005	Cancer J Clin2005，55，3：	1
19	Phase Ⅰ/Ⅱ trial of IDEC -Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20( + ) B - cell non - hodgkin' s lymphoma显示文摘	WITZIG T E WHITE C A WISEMAN G A	1999	J Clin Oncol1999，17，2：	1
20	Targeting apoptosis pathways in cancer therapy显示文摘	GHOBRIAL I M WITZIG T E ADJEI A A	2005	CA Cancer J Clin2005，55，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示